![Sture Jan-Gunnar Gustafsson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sture Jan-Gunnar Gustafsson
Directeur/Bestuurslid bij Ceffort AB
Profiel
Sture Jan-Gunnar Gustafsson is currently working as a Director at Ceffort AB.
Previously, he worked as SVP-Process Development & Manufacturing at Resistentia Pharmaceuticals AB.
He holds an MBA from the University of Stockholm.
Actieve functies van Sture Jan-Gunnar Gustafsson
Bedrijven | Functie | Begin |
---|---|---|
Ceffort AB
![]() Ceffort AB BiotechnologyHealth Technology Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Sture Jan-Gunnar Gustafsson
Bedrijven | Functie | Einde |
---|---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Corporate Officer/Principal | 24-06-2010 |
Opleiding van Sture Jan-Gunnar Gustafsson
University of Stockholm | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
Ceffort AB
![]() Ceffort AB BiotechnologyHealth Technology Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden. | Health Technology |